AzurTec

AzurTec is a clinical-stage biotechnology company focused on developing next-generation topical therapies for immune-mediated dermatological conditions. The company utilizes a "soft drug" design strategy, creating potent therapeutic agents that remain active in the skin but are quickly metabolized into inactive forms once they enter the bloodstream, thereby reducing systemic toxicity. Its lead candidate, AZT-001, is a topical Janus kinase (JAK) inhibitor currently in clinical development for atopic dermatitis. Founded by industry veterans with a track record in dermatology, AzurTec seeks to address the significant unmet need for safe, long-term treatments for chronic skin inflammation.